1328 related articles for article (PubMed ID: 16712668)
21. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
[TBL] [Abstract][Full Text] [Related]
22. [DelD631: a novel mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN2A)].
Yao B; Liu X; Dong TT; Chen X; Huang ZM; Weng JP
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(28):1962-5. PubMed ID: 17923033
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
24. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
25. Genetic testing in multiple endocrine neoplasia and related syndromes.
Calender A
Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
[TBL] [Abstract][Full Text] [Related]
26. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
27. [C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].
Benazzouz B; Hafidi A; Benkhira S; Chraibi A; Kadiri A; Hilal L
Bull Cancer; 2008 Apr; 95(4):457-63. PubMed ID: 18495576
[TBL] [Abstract][Full Text] [Related]
28. RET mutations in exons 13 and 14 of FMTC patients.
Bolino A; Schuffenecker I; Luo Y; Seri M; Silengo M; Tocco T; Chabrier G; Houdent C; Murat A; Schlumberger M
Oncogene; 1995 Jun; 10(12):2415-9. PubMed ID: 7784092
[TBL] [Abstract][Full Text] [Related]
29. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
30. Molecular advances in medullary thyroid cancer diagnostics.
Hubner RA; Houlston RS
Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
[TBL] [Abstract][Full Text] [Related]
31. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
32. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
[TBL] [Abstract][Full Text] [Related]
33. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
[TBL] [Abstract][Full Text] [Related]
34. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
[TBL] [Abstract][Full Text] [Related]
35. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
[TBL] [Abstract][Full Text] [Related]
36. [Medullary thyroid carcinoma and some of its particularities].
Sidibé el H
Sante; 2007; 17(1):51-5. PubMed ID: 17897902
[TBL] [Abstract][Full Text] [Related]
37. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
38. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
[TBL] [Abstract][Full Text] [Related]
39. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B
J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480
[TBL] [Abstract][Full Text] [Related]
40. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
